Ypsomed (YPSN) CMD 2025 Presentation summary

Strategic priorities and transformation

• Transitioning to a pure-play injection specialist, divesting non-core businesses from 2022 to 2026, including diabetes care and contract manufacturing.

• Focus on innovation, adapting to a maturing industry, and building global but local capacity.

• Evolving into a B2B company, expanding its market-leading position in self-injection devices.

• Five key messages: clear strategic priorities, exposure to high-growth markets, relentless innovation, global expansion with operational excellence, and solid financial foundations.

Market trends and growth drivers

• Benefiting from strong market growth drivers: selfcare at home, biologics, biosimilars, and incretins.

• Incretins market expected to be the strongest growth driver, with 47 clinical projects and 34 clients in the pipeline.

• Global market for autoinjectors and pens is sizeable and fast-growing, with a 27% CAGR in non-captive segments.

• Substantial barriers to entry include engineering know-how, regulatory requirements, and capital intensity.

Innovation and product portfolio

• Largest global portfolio for pens and autoinjectors, with three new platforms (YpsoFlow, YpsoDot, YpsoLoop) launching in 2025.

• Innovation strategy focused on solving real client needs and sustainability.

• 32 ongoing innovation projects, 1,614 patents in 30 countries, and a dedicated team of 40 core members.

• Device portfolio tailored to pharma needs: high-dosage, interchangeability, sustainability, and usability.